Alvotech will implement a single-use biomanufacturing automation platform, combining best of breed bioprocess equipment from upstream through downstream. This will provide Alvotech with flexible and efficient manufacturing capacity and scale-up capabilities, allowing Alvotech to reach its ambitions to become a global leader in the high-growth biopharmaceutical industry
They are currently building a state of the art 12 thousand square meter manufacturing and laboratory facility in the science park of the University of Iceland. The University is an innovative society for housing research institutes, university faculties, research students and knowledge-based companies, including start-ups and developed enterprises.
This new site will provide Alvotech with access to a new state-of-the-art, fully vertically integrated biologics manufacturing plant to continue developing its six key biosimilar molecules in development.